AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $150,678 | +31.5% | 2,979 | +21.4% | 0.01% | +33.3% |
| Q2 2023 | $114,577 | +51.2% | 2,454 | +23.9% | 0.01% | +50.0% |
| Q1 2023 | $75,793 | -35.8% | 1,981 | -8.1% | 0.00% | -20.0% |
| Q4 2022 | $118,149 | +95.4% | 2,156 | +21.4% | 0.01% | +66.7% |
| Q3 2022 | $60,473 | +260.3% | 1,776 | 0.0% | 0.00% | +200.0% |
| Q2 2022 | $16,783 | -33.4% | 1,776 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $25,201 | -84.2% | 1,776 | -76.4% | 0.00% | -50.0% |
| Q4 2021 | $159,175 | -5.4% | 7,526 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $168,206 | -9.9% | 7,526 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $186,720 | +66.7% | 7,526 | +95.0% | 0.00% | +50.0% |
| Q1 2021 | $111,979 | +12.4% | 3,860 | 0.0% | 0.00% | +100.0% |
| Q4 2020 | $99,588 | -16.2% | 3,860 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $118,849 | +23.6% | 3,860 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $96,191 | – | 3,860 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $168,435,000 | 13.00% |
| venBio Partners LLC | 2,444,311 | $63,063,000 | 5.57% |
| Versant Venture Management, LLC | 777,727 | $20,065,000 | 2.08% |
| Vivo Capital, LLC | 633,426 | $16,342,000 | 0.73% |
| Redmile Group, LLC | 2,322,557 | $59,922,000 | 0.73% |
| Boxer Capital, LLC | 831,495 | $21,453,000 | 0.69% |
| Integral Health Asset Management, LLC | 85,000 | $2,193,000 | 0.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 35,179 | $908,000 | 0.53% |
| HighVista Strategies LLC | 27,739 | $716,000 | 0.46% |
| Cormorant Asset Management, LP | 742,549 | $19,158,000 | 0.46% |